The directors who were on the board when they were trying different trials which didn't work to the TGA or FDA standard should be the one leaving the board... i.e Roger and Martin who should be leaving OSL not Chris... IMO.
Martin is on the board of another company which is also failing big time and he did the same performance for OSL so he should be the one leaving first but I guess where can he go ? .. .IMO... !
Chris is the one who got Nigel in and he should be the one staying while all other three directors i.e. Roger, Martin and Michael should leave OSL. Chris departure is OSL loss... IMO.
Otto is OK but as others mentioned his background is more into technology not in bioscience even though he is on the board of Rhythm Bioscience... so not sure what he might end-up achieving in OSL. I avoided Rhythm Bioscience long ago because the board is full of non-science personality except the one key scientist.
Ann: Otto Buttula appointed to the Board of OncoSil, page-6
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.002(22.2%) |
Mkt cap ! $37.38M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.2¢ | 1.0¢ | $271.4K | 26.46M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 7073500 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 75694 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |